Literature DB >> 16080489

Immunohistochemical staining of estrogen and progesterone receptors: aspects for evaluating positivity and defining the cutpoints.

Päivi Jalava1, Teijo Kuopio, Riikka Huovinen, Juhana Laine, Yrjö Collan.   

Abstract

BACKGROUND: Estrogen (ER) and progesterone (PgR) receptors are predictive and prognostic factors in breast cancer. The most suitable immunohistochemical cutpoints for dividing the tumors in hormone receptor-negatives and -positives may, however, need more consideration. We examined the association between breast cancer survival and cutpoints assessed by four different models. We looked for evidence for which patient subgroups could be handled best through applying different cutpoints.
MATERIALS AND METHODS: Three hundred and twenty-four samples of invasive breast cancer were immunohistochemically stained for ER and PgR, bcl-2 and erbB2. Fractions of ER- and PgR-positive cells and also ER and PgR staining scores were assessed. The fractions of stained cells and staining scores, respectively, were determined on the whole section area, and the area of most intense staining. Candidate cutpoints, dividing the patients into good and poor prognosis groups, were tested among all patients group, N+ and N- groups, premenopausal and postmenopausal patient groups. The correlation between immunohistochemistry results of ER, PgR, bcl-2 and erbB2 as well as SMI (standardized mitotic index), patient age, tumor size and axillary lymph node status were tested.
RESULTS: The ER score was correlated with age, SMI and bcl-2 positivity. The PgR score was correlated with erbB2 and bcl-2. Lobular carcinomas had higher staining scores of ER and PgR than ductal carcinomas.
CONCLUSION: In this material, ER was correlated with factors reflecting the differentiation of the tumor. On the basis of the ER and PgR immunohistochemistry cutpoint analysis, we found that the optimal cutpoints in different patient groups may not be the same.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16080489

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  9 in total

1.  American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer.

Authors:  M Elizabeth H Hammond; Daniel F Hayes; Mitch Dowsett; D Craig Allred; Karen L Hagerty; Sunil Badve; Patrick L Fitzgibbons; Glenn Francis; Neil S Goldstein; Malcolm Hayes; David G Hicks; Susan Lester; Richard Love; Pamela B Mangu; Lisa McShane; Keith Miller; C Kent Osborne; Soonmyung Paik; Jane Perlmutter; Anthony Rhodes; Hironobu Sasano; Jared N Schwartz; Fred C G Sweep; Sheila Taube; Emina Emilia Torlakovic; Paul Valenstein; Giuseppe Viale; Daniel Visscher; Thomas Wheeler; R Bruce Williams; James L Wittliff; Antonio C Wolff
Journal:  Arch Pathol Lab Med       Date:  2010-06       Impact factor: 5.534

2.  Discordance between original and central laboratories in ER and HER2 results in a diverse, population-based sample.

Authors:  Jennifer J Griggs; Ann S Hamilton; Kendra L Schwartz; Weiqiang Zhao; Paul H Abrahamse; Dafydd G Thomas; Julie M Jorns; Rachel Jewell; Maria E Sibug Saber; Reina Haque; Steven J Katz
Journal:  Breast Cancer Res Treat       Date:  2016-11-29       Impact factor: 4.872

Review 3.  American Society of Clinical Oncology/College Of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer.

Authors:  M Elizabeth H Hammond; Daniel F Hayes; Mitch Dowsett; D Craig Allred; Karen L Hagerty; Sunil Badve; Patrick L Fitzgibbons; Glenn Francis; Neil S Goldstein; Malcolm Hayes; David G Hicks; Susan Lester; Richard Love; Pamela B Mangu; Lisa McShane; Keith Miller; C Kent Osborne; Soonmyung Paik; Jane Perlmutter; Anthony Rhodes; Hironobu Sasano; Jared N Schwartz; Fred C G Sweep; Sheila Taube; Emina Emilia Torlakovic; Paul Valenstein; Giuseppe Viale; Daniel Visscher; Thomas Wheeler; R Bruce Williams; James L Wittliff; Antonio C Wolff
Journal:  J Clin Oncol       Date:  2010-04-19       Impact factor: 44.544

4.  Clinical relevance of the reappraisal of negative hormone receptor expression in breast cancer.

Authors:  António E Pinto; Filipa Areia; Teresa Pereira; Paula Cardoso; Mariana Aparício; Giovani L Silva; Mónica C Ferreira; Saudade André
Journal:  Springerplus       Date:  2013-08-09

5.  Lymph node status as a guide to selection of available prognostic markers in breast cancer: the clinical practice of the future?

Authors:  A Elzagheid; T Kuopio; S Pyrhönen; Y Collan
Journal:  Diagn Pathol       Date:  2006-11-08       Impact factor: 2.644

6.  CD105 expression on CD34-negative spindle-shaped stromal cells of primary tumor is an unfavorable prognostic marker in early breast cancer patients.

Authors:  Leandro Marcelo Martinez; Vivian Labovsky; María de Luján Calcagno; Kevin Mauro Davies; Hernán Garcia Rivello; Hernán Garcia Rivello; Maria Silvia Bianchi; Alejandra Wernicke; Valeria Beatriz Fernández Vallone; Valeria Beatriz Fernández Vallone; Norma Alejandra Chasseing
Journal:  PLoS One       Date:  2015-03-24       Impact factor: 3.240

7.  Relationship Study of The Verified H uman Epidermal Growth Factor Receptor 2 Amplification with Other Tumor Markers and Clinicohistopathological Characteristics in Patients with Invasive Breast Cancer, Using Chromogenic In Situ Hybridization.

Authors:  Abdolazim Sarli; Hossein Mozdarani; Nasser Rakhshani; Sohail Mozdarani
Journal:  Cell J       Date:  2019-06-15       Impact factor: 2.479

8.  Pathobiological features of breast tumours in the State of Kuwait: a comprehensive analysis.

Authors:  Farid Saleh; Suad Abdeen
Journal:  J Carcinog       Date:  2007-09-24

9.  Proliferative activity in Libyan breast cancer with comparison to European and Central African patients.

Authors:  Jamela Boder; Fathi Abdalla; Mohamed Elfagieh; Abdelbaset Buhmeida; Yrjö Collan
Journal:  Biomed Res Int       Date:  2013-09-11       Impact factor: 3.411

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.